SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Akeso Reports Ivonescimab Survival Advantage in Phase III Biliary Cancer Study

Summit Therapeutics said its partner Akeso announced positive results from the Phase III HARMONi-GI1 study in China, comparing ivonescimab plus chemotherapy with durvalumab plus chemotherapy in first-line advanced biliary tract cancer.

9926SMMT
SquawkNews Desk

Related stories

Microsoft Says Consumer Services Recovered, Enterprise Recovery Ongoing Microsoft said its consumer products services had fully recovered at 4:10 p.m. UTC Friday, while Microsoft 365 enterprise services were seeing some sustained recovery. The company M impact | EQUITY | Nov 14, 2026, 05:32 AM UTC Microsoft Says Consumer Products Services Recovered Microsoft said its consumer products services had fully recovered, while Microsoft 365 enterprise services were seeing a sustained recovery. M impact | EQUITY | Nov 14, 2026, 05:17 AM UTC Microsoft restores consumer product services after outage Microsoft said its consumer product services have been restored; other services are not included in the update. M impact | EQUITY | Nov 14, 2026, 05:10 AM UTC Microsoft Outlook Begins Returning After Global Microsoft 365 Disruption Microsoft said it was working to restore email access after a global Microsoft 365 disruption. Industry executives warned of risks from dependence on a single technology provider. M impact | EQUITY | Nov 14, 2026, 04:31 AM UTC Tesla sells Cybercab to first private customers Reuters reports Tesla is offering its Cybercab to its first private customers. M impact | EQUITY | Nov 14, 2026, 04:23 AM UTC Microsoft says affected services fully recovered L impact | EQUITY | Nov 14, 2026, 04:14 AM UTC